Helmsley Breakthrough Initiative

The Helmsley Breakthrough Initiative was launched to drive innovation in the field of type 1 diabetes (T1D) by supporting early-stage or pilot studies. Intended to advance projects that have a strong rationale but little or no preliminary data, the goal is to generate new hypotheses about how T1D develops and new therapeutic strategies to treat it.  


In its first round of funding, the Helmsley Breakthrough Initiative committed an investment of $1,100,000 for pilot studies of early-stage drug therapies that were designed to promote beta cell function or prevent beta cell loss.


The latest opportunity from the Helmsley Breakthrough Initiative focuses on supporting early-stage studies of unique clinical cases of type 1 diabetes.